Mathematical model for the estrogen paradox in breast cancer treatment
- 3 March 2022
- journal article
- research article
- Published by Springer Nature in Journal of Mathematical Biology
- Vol. 84 (4) , 1-32
Abstract
Estrogen is known to stimulate the growth of breast cancer, but is also effective in treating the disease. This is referred to as the“estrogen paradox”. Furthermore, short-term treatment with estrogen can successfully eliminate breast cancer, whereas long-term treatment can cause cancer recurrence. Studies highlighted clinical correlations between estrogen and the protein p53 which plays a pivotal role in breast cancer suppression. We sought to investigate how the interplay between estrogen and p53 impacts the dynamics of breast cancer, and further explore if this could be a plausible explanation for the estrogen paradox and the paradoxical tumor recurrence that results from prolonged treatment with estrogen. For this, we propose a novel ODE based mathematical model that accounts for dormant and active cancer cells, along with the estrogen hormone and the p53 protein. We analyze the model’s global stability behavior using the Poincaré-Bendixson theorem and results from differential inequalities. We also perform a bifurcation analysis and carry out numerical simulations that elucidate the roles of estrogen and p53 in the estrogen paradox and its long term estrogen paradoxical effect. The mathematical and numerical analyses suggest that the apparent paradoxical role of estrogen could be the result of an interplay between estrogen and p53, and provide explicit conditions under which the paradoxical effect of long-term treatment may be prevented.Keywords
Funding Information
- DST/NRF SARChI Chair in Mathematical Models and Methods in Biosciences and Bioengineering at the University of Pretoria, South Africa
- Center of Excellence in Mathematical and Statistical Sciences (DST-NRF COE-MaSS), South Africa
This publication has 44 references indexed in Scilit:
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulationProceedings of the National Academy of Sciences of the United States of America, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast CancerJAMA, 2009
- Transcriptional Regulation of Estrogen Receptor-α by p53 in Human Breast Cancer CellsCancer Research, 2009
- Cellular interactions in the vascular niche: implications in the regulation of tumor dormancyAPMIS, 2008
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids, 2007
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- Influence of Synthetic Oestrogens on Advanced Malignant DiseaseBMJ, 1944